LY5

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 562712

CAS#: 1436382-03-4

Description: LY5 is a STAT3 inhibitor. It acts by inhibiting cell viability, cell migration, and angiogenesis in medulloblastoma cells.

Chemical Structure

img
LY5
CAS# 1436382-03-4
Instruction

Theoretical Analysis

MedKoo Cat#: 562712
Name: LY5
CAS#: 1436382-03-4
Chemical Formula: C15H11N3O4S
Exact Mass: 329.05
Molecular Weight: 329.330
Elemental Analysis: C, 54.71; H, 3.37; N, 12.76; O, 19.43; S, 9.73

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Synonym: LY5; LY-5; LY 5;

IUPAC/Chemical Name: 5,8-Dioxo-6-(pyridin-3-ylamino)-5,8-dihydro-naphthalene-1-sulfonic acid amide

InChi Key: GSGMKINCHGAOPK-UHFFFAOYSA-N

InChi Code: InChI=1S/C15H11N3O4S/c16-23(21,22)13-5-1-4-10-14(13)12(19)7-11(15(10)20)18-9-3-2-6-17-8-9/h1-8,18H,(H2,16,21,22)

SMILES Code: O=S(C(C=CC=C1C(C(NC2=CC=CN=C2)=C3)=O)=C1C3=O)(N)=O

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 329.33 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Qiao X, Rao P, Zhang Y, Liu L, Pang M, Wang H, Hu M, Tian X, Zhang J, Zhao Y, Wang XM, Wang C, Yu H, Guo F, Cao Q, Wang Y, Wang YM, Zhang GY, Lee VW, Alexander SI, Zheng G, Harris DCH. Redirecting TGF-β Signaling through the β-Catenin/Foxo Complex Prevents Kidney Fibrosis. J Am Soc Nephrol. 2018 Feb;29(2):557-570. doi: 10.1681/ASN.2016121362. Epub 2017 Nov 27. PubMed PMID: 29180394; PubMed Central PMCID: PMC5791062.

2: Chiba Y, Mizoguchi I, Furusawa J, Hasegawa H, Ohashi M, Xu M, Owaki T, Yoshimoto T. Interleukin-27 Exerts Its Antitumor Effects by Promoting Differentiation of Hematopoietic Stem Cells to M1 Macrophages. Cancer Res. 2018 Jan 1;78(1):182-194. doi: 10.1158/0008-5472.CAN-17-0960. Epub 2017 Nov 1. PubMed PMID: 29093008.

3: Yu PY, Gardner HL, Roberts R, Cam H, Hariharan S, Ren L, LeBlanc AK, Xiao H, Lin J, Guttridge DC, Mo X, Bennett CE, Coss CC, Ling Y, Phelps MA, Houghton P, London CA. Target specificity, in vivo pharmacokinetics, and efficacy of the putative STAT3 inhibitor LY5 in osteosarcoma, Ewing's sarcoma, and rhabdomyosarcoma. PLoS One. 2017 Jul 27;12(7):e0181885. doi: 10.1371/journal.pone.0181885. eCollection 2017. PubMed PMID: 28750090; PubMed Central PMCID: PMC5531494.

4: Wang Y, Huang D, Chen KY, Cui M, Wang W, Huang X, Awadellah A, Li Q, Friedman A, Xin WW, Di Martino L, Cominelli F, Miron A, Chan R, Fox JG, Xu Y, Shen X, Kalady MF, Markowitz S, Maillard I, Lowe JB, Xin W, Zhou L. Fucosylation Deficiency in Mice Leads to Colitis and Adenocarcinoma. Gastroenterology. 2017 Jan;152(1):193-205.e10. doi: 10.1053/j.gastro.2016.09.004. Epub 2016 Sep 14. PubMed PMID: 27639802; PubMed Central PMCID: PMC5164974.

5: Tan X, Fujiu K, Manabe I, Nishida J, Yamagishi R, Terashima Y, Matsushima K, Kaburaki T, Nagai R, Yanagi Y. Choroidal Neovascularization Is Inhibited in Splenic-Denervated or Splenectomized Mice with a Concomitant Decrease in Intraocular Macrophage. PLoS One. 2016 Aug 17;11(8):e0160985. doi: 10.1371/journal.pone.0160985. eCollection 2016. PubMed PMID: 27532664; PubMed Central PMCID: PMC4988653.

6: Moro-Sibilot L, Blanc P, Taillardet M, Bardel E, Couillault C, Boschetti G, Traverse-Glehen A, Defrance T, Kaiserlian D, Dubois B. Mouse and Human Liver Contain Immunoglobulin A-Secreting Cells Originating From Peyer's Patches and Directed Against Intestinal Antigens. Gastroenterology. 2016 Aug;151(2):311-23. doi: 10.1053/j.gastro.2016.04.014. Epub 2016 Apr 27. PubMed PMID: 27132185.

7: Zhao C, Wang W, Yu W, Jou D, Wang Y, Ma H, Xiao H, Qin H, Zhang C, Lü J, Li S, Li C, Lin J, Lin L. A novel small molecule STAT3 inhibitor, LY5, inhibits cell viability, colony formation, and migration of colon and liver cancer cells. Oncotarget. 2016 Mar 15;7(11):12917-26. doi: 10.18632/oncotarget.7338. PubMed PMID: 26883202; PubMed Central PMCID: PMC4914331.

8: Wu X, Xiao H, Wang R, Liu L, Li C, Lin J. Persistent GP130/STAT3 Signaling Contributes to the Resistance of Doxorubicin, Cisplatin, and MEK Inhibitor in Human Rhabdomyosarcoma Cells. Curr Cancer Drug Targets. 2016;16(7):631-8. PubMed PMID: 26373715; PubMed Central PMCID: PMC5014400.

9: Kumar A. Malignant transformation of mature T cells after gammaretrovirus mediated transfer of nucleophosmin-anaplastic lymphoma kinase oncogene. Indian J Pathol Microbiol. 2015 Jul-Sep;58(3):301-6. doi: 10.4103/0377-4929.162835. PubMed PMID: 26275250.

10: Liang ZW, Guo KM, Dai XF, Liu LY, Xu SQ, Zhao LJ, Li FB, Wang HL. [Protective effect of lycopene on human spermatozoa during cryopreservation and its mechanism]. Zhonghua Nan Ke Xue. 2015 Jun;21(6):521-6. Chinese. PubMed PMID: 26242042.

11: Zhao C, Xiao H, Wu X, Li C, Liang G, Yang S, Lin J. Rational combination of MEK inhibitor and the STAT3 pathway modulator for the therapy in K-Ras mutated pancreatic and colon cancer cells. Oncotarget. 2015 Jun 10;6(16):14472-87. PubMed PMID: 25961376; PubMed Central PMCID: PMC4546480.

12: Xiao H, Bid HK, Jou D, Wu X, Yu W, Li C, Houghton PJ, Lin J. A novel small molecular STAT3 inhibitor, LY5, inhibits cell viability, cell migration, and angiogenesis in medulloblastoma cells. J Biol Chem. 2015 Feb 6;290(6):3418-29. doi: 10.1074/jbc.M114.616748. Epub 2014 Oct 13. PubMed PMID: 25313399; PubMed Central PMCID: PMC4319011.

13: Hermida MD, Doria PG, Taguchi AM, Mengel JO, dos-Santos W. Leishmania amazonensis infection impairs dendritic cell migration from the inflammatory site to the draining lymph node. BMC Infect Dis. 2014 Aug 20;14:450. doi: 10.1186/1471-2334-14-450. PubMed PMID: 25142021; PubMed Central PMCID: PMC4143564.

14: Ueda T, Fujita A, Ogawa R, Itoh Y, Fukunaga Y, Shimada T, Migita M. Adipose-derived stromal cells grown on a hydroxyapatite scaffold can support hematopoiesis in regenerated bone marrow in vivo. Cell Biol Int. 2014 Jun;38(6):790-8. doi: 10.1002/cbin.10254. Epub 2014 Apr 24. PubMed PMID: 24474575.

15: Yang L, Fu S, Khan MA, Zeng W, Fu J. Molecular cloning and development of RAPD-SCAR markers for Dimocarpus longan variety authentication. Springerplus. 2013 Oct 3;2:501. doi: 10.1186/2193-1801-2-501. eCollection 2013. PubMed PMID: 24130961; PubMed Central PMCID: PMC3795202.

16: Yu W, Xiao H, Lin J, Li C. Discovery of novel STAT3 small molecule inhibitors via in silico site-directed fragment-based drug design. J Med Chem. 2013 Jun 13;56(11):4402-12. doi: 10.1021/jm400080c. Epub 2013 May 16. PubMed PMID: 23651330.

17: Wienecke J, Hebel K, Hegel KJ, Pierau M, Brune T, Reinhold D, Pethe A, Brunner-Weinzierl MC. Pro-inflammatory effector Th cells transmigrate through anti-inflammatory environments into the murine fetus. Placenta. 2012 Jan;33(1):39-46. doi: 10.1016/j.placenta.2011.10.014. Epub 2011 Nov 16. PubMed PMID: 22093381.

18: Hlobeňová T, Sefc L, Chang KT, Savvulidi F, Michalová J, Nečas E. B-lymphopoiesis gains sensitivity to subsequent inhibition by estrogens during final phase of fetal development. Dev Comp Immunol. 2012 Feb;36(2):385-9. doi: 10.1016/j.dci.2011.07.009. Epub 2011 Aug 10. PubMed PMID: 21854803.

19: Vargas CL, Poursine-Laurent J, Yang L, Yokoyama WM. Development of thymic NK cells from double negative 1 thymocyte precursors. Blood. 2011 Sep 29;118(13):3570-8. doi: 10.1182/blood-2011-06-359679. Epub 2011 Aug 5. PubMed PMID: 21821702; PubMed Central PMCID: PMC3186333.

20: Rasmussen KD, O'Carroll D. The miR-144/451eGFP allele, a novel tool for resolving the erythroid potential of hematopoietic precursors. Blood. 2011 Sep 15;118(11):2988-92. doi: 10.1182/blood-2011-04-350728. Epub 2011 Jul 25. PubMed PMID: 21791432.